Literature DB >> 11369293

Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery.

D J. Payne1, P V. Warren, D J. Holmes, Y Ji, J T. Lonsdale.   

Abstract

In this review we demonstrate how the interplay of genomics, bioinformatics and genomic technologies has enabled an in-depth analysis of the component enzymes of the bacterial fatty-acid biosynthesis pathway as a source of novel antibacterial targets. This evaluation has revealed that many of the enzymes are potentially selective, broad-spectrum antibacterial targets. We also illustrate the suitability of some of these targets for HTS. Furthermore, we discuss how the availability of a robust selectivity assay, mode-of-action assays and numerous crystal structures provide an excellent set of tools with which to initiate integrated programs of research to identify novel antibiotics targeted at these enzymes.

Entities:  

Year:  2001        PMID: 11369293     DOI: 10.1016/s1359-6446(01)01774-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  31 in total

1.  Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae.

Authors:  Pan F Chan; Karen M O'Dwyer; Leslie M Palmer; Jennifer D Ambrad; Karen A Ingraham; Chi So; Michael A Lonetto; Sanjoy Biswas; Martin Rosenberg; David J Holmes; Magdalena Zalacain
Journal:  J Bacteriol       Date:  2003-03       Impact factor: 3.490

2.  Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery.

Authors:  Hans Peter Fischer; Nina A Brunner; Bernd Wieland; Jesse Paquette; Ludwig Macko; Karl Ziegelbauer; Christoph Freiberg
Journal:  Genome Res       Date:  2004-01       Impact factor: 9.043

3.  Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques.

Authors:  Jinhong Ren; Tina L Mistry; Pin-Chih Su; Shahila Mehboob; Robel Demissie; Leslie Wo-Mei Fung; Arun K Ghosh; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-04-22       Impact factor: 2.823

4.  Substrate recognition by β-ketoacyl-ACP synthases.

Authors:  Janine G Borgaro; Andrew Chang; Carl A Machutta; Xujie Zhang; Peter J Tonge
Journal:  Biochemistry       Date:  2011-11-17       Impact factor: 3.162

Review 5.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Exogenous fatty acid metabolism in bacteria.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochimie       Date:  2017-06-28       Impact factor: 4.079

7.  Docking and molecular dynamics studies on triclosan derivatives binding to FabI.

Authors:  Xuyun Yang; Junrui Lu; Ming Ying; Jiangbei Mu; Peichun Li; Yue Liu
Journal:  J Mol Model       Date:  2017-01-07       Impact factor: 1.810

8.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

10.  Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.

Authors:  Lei Zhu; Jinshui Lin; Jincheng Ma; John E Cronan; Haihong Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.